Reverse engineering of Alzheimer's disease based on biomarker pathways analysis

Area of Science:

• Neuroscience
• Biochemistry
• Genetics

Background:

• Alzheimer's disease (AD) presents a significant societal challenge, with its underlying molecular mechanisms remaining poorly understood.
• Identifying the precise molecular failures that initiate AD is critical for developing effective interventions.

Purpose of the Study:

• To investigate novel molecular biomarkers in cerebrospinal fluid (CSF) for defining the early biochemical events in Alzheimer's disease.
• To correlate changes in these biomarkers with disease progression from mild cognitive impairment (MCI) to AD.
• To identify biochemical conditions and genetic factors associated with AD onset by tracking biomarker origins.

Main Methods:

• Utilized a novel panel of biomolecules found in the CSF of AD patients.
• Analyzed the relative abundance of these molecular markers in relation to disease progression (MCI to AD).
• Integrated protein marker analysis with genetic factor assessment.

Main Results:

• Demonstrated that changes in specific CSF biomolecules correlate with the progression of Alzheimer's disease.
• Established an association between these molecular markers and the transition from mild cognitive impairment to AD.
• Identified potential biochemical origins and genetic influences contributing to AD pathogenesis.

Conclusions:

• Novel CSF molecular biomarkers can help define the early biochemical landscape of Alzheimer's disease.
• Tracking these biomarkers aids in identifying predisposing biochemical conditions and genetic factors for AD.
• This approach allows for a redefined understanding of AD based on its underlying molecular pathways.